ASIA News
Metronom sees its "disruptive" technology pushing the advancement of digital diabetes management, providing patients with diabetes-related education, data analysis and other services.
The conpany uses its own spectroscopic technology to detect, analyse, and quantify molecular information.
The companies will develop a solution based on a new technique of flow cytometry that enables fast and accurate cell analysis using AI.
Founded in 2016, the company runs an online insurance marketplace and a platform for medical crowdfunding.
The ArtiSential devices act as an extension of a surgeon's arm, mimicking the movement of its user's hand, wrist and fingers.
The company hopes to equip China’s hospitals with digital surgery solutions to enable better health outcomes.
Funds from this investing round will be used for the expansion of its solutions and services.
Customers of the insurance firm are able to access a suite of telemedicine services via their My AIA app.
The company will use the funds to expand its products and employ more staff in India and the US.
The company states that the study was designed to minimise bias in assessing the solution’s impact on diagnostic accuracy.